A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 08 Feb 2019
At a glance
- Drugs REGN-3048 (Primary) ; REGN-3051 (Primary)
- Indications Middle East respiratory syndrome coronavirus
- Focus Adverse reactions; First in man
- 30 Jan 2019 Status changed from active, no longer recruiting to completed.
- 03 Jan 2019 Planned End Date changed from 15 Jun 2019 to 19 Jan 2019.
- 03 Jan 2019 Planned primary completion date changed from 15 Dec 2018 to 19 Jan 2019.